Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 12 - 12 crawled time : 16:20 save search
Top 10 Key Tactics The Pros Use For magasin steroide paris
Published: 2021-12-12 (Crawled : 16:20) - oncocyte.com
OCX | News | $2.3 -6.31% -6.74% 41K
|
Health Technology
| Email alert
Add to watchlist
Cosa può insegnarti Alberto Savoia cani steroidi
Published: 2021-12-12 (Crawled : 16:20) - oncocyte.com
OCX | News | $2.3 -6.31% -6.74% 41K
|
Health Technology
| Email alert
Add to watchlist
I 5 migliori libri su steroidi non fanno effetto
Published: 2021-12-12 (Crawled : 16:20) - oncocyte.com
OCX | News | $2.3 -6.31% -6.74% 41K
|
Health Technology
| Email alert
Add to watchlist
Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia
Published: 2021-12-12 (Crawled : 16:20) - immunogen.com
IMGN | News | $31.23 0.03% 49M
|
Health Technology
| Email alert
Add to watchlist
imgn632 myeloid leukemia phase 1b leukemia phase 1 positive acute myeloid leukemia phase 2b
Missed Out on Shiba Inu? EverGrow Might Be The Next Big Crypto To Explode in 2022
Published: 2021-12-12 (Crawled : 16:20) - prnewswire.com
CRCW | $0.0015 27.78% 8.5M
|
Information
| Email alert
Add to watchlist
Jazz Pharmaceuticals Presents Positive Interim Phase 2/3 Results of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at ASH 2021 Annual Meeting
Published: 2021-12-12 (Crawled : 16:20) - prnewswire.com
JAZZ | $108.38 -1.18% -1.19% 400K
|
Health Technology
| Email alert
Add to watchlist
phase 2 phase 2/3 leukemia positive results
Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting
Published: 2021-12-12 (Crawled : 16:20) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
| Email alert
Add to watchlist
ema trial phase 1
Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data in Polycythemia Vera (PV) at ASH 2021 Annual Meeting
Published: 2021-12-12 (Crawled : 16:20) - prnewswire.com
PTGX S | $25.68 -4.36% -4.56% 330K
|
Health Technology
| Email alert
Add to watchlist
phase 2 therapeutics
Beam Therapeutics Outlines Long-term Strategy for Base Editing Programs in Sickle Cell Disease and Provides Preclinical Data Updates at ASH
Published: 2021-12-12 (Crawled : 16:20) - globenewswire.com
BEAM | $22.74 -3.11% -3.21% 1.1M
|
Health Technology
| Email alert
Add to watchlist
therapeutics disease preclinical pre-clinical
GBT Presents Positive New Data on Oxbryta® (voxelotor) in Patients with Sickle Cell Disease at ASH Annual Meeting and Exposition
Published: 2021-12-12 (Crawled : 16:20) - globenewswire.com
GBT | $68.49 0.02% -0.02%
|
Health Technology
| Email alert
Add to watchlist
oxbryta disease positive
Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting
Published: 2021-12-12 (Crawled : 16:20) - globenewswire.com
NRIX 6 d | $13.73 -2.83% -2.91% 520K
|
Health Technology
| Email alert
Add to watchlist
nx-5948 ema clearance trial therapeutics preclinical phase 1 pre-clinical
ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic Syndrome
Published: 2021-12-12 (Crawled : 16:20) - globenewswire.com
ALXO M | $16.24 4.77% 4.56% 440K
|
Commercial Services
| Email alert
Add to watchlist
aspen-02 ongoing phase 1 syndros
New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases
Published: 2021-12-12 (Crawled : 16:20) - globenewswire.com
SLNCF | $8.0 -65.0% 630
|
Health Technology
| Email alert
Add to watchlist
SLN | $22.33 -0.8% -0.81% 110K
|
Health Technology
| Email alert
Add to watchlist
sln124 health ema disease potential
Sana Biotechnology Presentations at 2021 ASH Annual Meeting Highlight Progress with Platforms and CAR T Cell Programs
Published: 2021-12-12 (Crawled : 16:20) - globenewswire.com
SANA | $8.58 6.06% 5.71% 1.2M
|
| Email alert
Add to watchlist
technology presentation biotech iot platform t-cell
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.